28 May 2025 - Utrecht

In this presentation, Genmab Scientist Wiggert Altenburg shares his personal journey from academic research to industry, providing an insider’s view of life at Genmab. He introduces the company’s global footprint, innovative antibody technologies, and research-driven culture. The session walks through the process of antibody discovery and development, from early-stage ideation to clinical trials, highlighting the importance of high-quality tools and cross-functional collaboration. Wiggert also reflects on his own transition from PhD studies to working in biotech, offering insights for students and early-career scientists interested in making a similar move.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. To help develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
For more information, please visit Genmab.com